GlassScriptPhysician profile
Kamal Gupta
NPI 1164415105
$3,108.89
in general payments reported to CMS, 2019-2025
28 companies · $961 in 2025
The $961 reported for 2025 was more than what 76% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $301 · 2020: $125 · 2021: $235 · 2022: $681 · 2023: $469 · 2024: $337 · 2025: $961.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,527 · Long Term Medical Supply Or Device Loan: $240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,527.06 |
| Long Term Medical Supply Or Device Loan | $240.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $535.16 | 2019-2024 | Clareon, Hydrus Microstent, Eysuvis |
| Alimera Sciences, INC. | $385.60 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $370.59 | 2020-2025 | Eylea Hd, Eylea |
| Bausch & Lomb Americas INC. | $312.15 | 2023-2025 | Scoutpro Osmolarity System, Xipere, Xiidra |
| Novartis Pharmaceuticals Corporation | $166.98 | 2019-2022 | |
| Lumenis Be INC | $162.00 | 2025 | M22 |
| Sun Pharmaceutical Industries INC. | $160.86 | 2019-2025 | Cequa |
| Astellas Pharma US INC | $144.58 | 2023-2025 | Izervay |
| Oyster Point Pharma, INC. | $110.50 | 2022-2025 | Tyrvaya, Ryzumvi |
| Abbvie INC. | $100.69 | 2022-2025 | |
| Biotissue Holdings INC. | $91.97 | 2021-2025 | |
| New World Medical,INC. | $65.06 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $45.42 | 2024-2025 | Xdemvy |
| Spark Therapeutics, INC. | $42.89 | 2019 | |
| Shire North American Group INC | $42.13 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $40.74 | 2021-2024 | Oxervate |
| Genentech USA, INC. | $39.50 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $38.92 | 2019-2020 | |
| Allergan, INC. | $37.45 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $35.12 | 2020-2021 | |
| Ucb, INC. | $28.39 | 2025 | Briviact |
| Apellis Pharmaceuticals, INC. | $27.93 | 2025 | |
| Horizon Therapeutics Plc | $27.30 | 2022-2023 | Tepezza |
| Sk Life Science, INC. | $26.69 | 2025 | |
| Amgen INC. | $24.52 | 2024 | Tepezza |
| Lkc Technologies, INC. | $17.70 | 2024 | |
| Lensar, INC. | $14.81 | 2023 | Lensar Laser System |
| Ocular Therapeutix, INC. | $13.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kamal Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.